$KMXBearishMed

CarMax Stock Falls 7% Over Lower Earnings In Q1

CarMax shares fell about 7% in Wednesday morning trading after the company reported lower Q1 earnings. CarMax said first-quarter profit declined to $185.63 million, or $1.31 per share, from $210.38 million, or $1.38 per share, a year earlier. The stock was trading around $48.32, down from $52.11 at the prior close.

8/10
8/10
Med
Bearish
Wednesday morning trading reaction to Q1 earnings decline
Risk-off/negative for discretionary retail/auto retail earnings momentum

Lower Q1 earnings are driving a near-term negative repricing for KMX.

CarMax shares fell ~7% after Q1 earnings declined to $185.63M, or $1.31/share, from $210.38M, or $1.38/share.

Bearish bias for the next session(s) as the earnings miss/decline is digested; follow-through depends on any guidance not provided here.

Background

The article reports CarMax’s Q1 earnings decline and the immediate stock reaction, but omits consensus estimates and forward guidance.

Why it matters

The disclosed EPS/earnings decline is the primary catalyst for the reported ~7% drop; traders may reassess near-term earnings power and valuation multiples.

Market relevance

Earnings decline with a same-day price drop creates a tradable negative catalyst for KMX, though the lack of guidance/estimate context limits precision.

Market effects

Adds to read-through risk for used-car/auto retail demand and earnings sensitivity to consumer conditions.

Primarily US equity sentiment; limited direct cross-region linkage from the provided facts.

Low—no international operations, macro, or supply-chain specifics mentioned.

Alternative perspectives

A single-quarter earnings decline may be temporary if demand stabilizes; without guidance or estimate context, the selloff could be overdone.

No details on revenue, margins, unit sales, or management commentary are provided; those could materially change the earnings quality assessment.

Key entities

  • CarMax, Inc.

    Subject of the article; Q1 earnings declined to $185.63M/$1.31 per share and shares fell ~7%.

Related articles

$KMXMed

Why CarMax Stock Zoomed Nearly 19% Higher in June

CarMax (KMX) shares rose nearly 19% in June after its June 17 Q1 FY2027 results. Net revenue was just over $8B (+6% YoY) and GAAP net income fell 12% to $186M, or $1.31/share, beating consensus. Analysts raised price targets, including Stephens’ Jeff Lick to $66 from $43, and insiders bought shares.

$KMXMed

Why CarMax Stock Plummeted Today

CarMax shares fell about 9% on Wednesday despite a better-than-expected fiscal Q1 report (ended May 31). The company posted EPS of $1.31 on revenue of $8.01B, beating analyst estimates, but its forward guidance came in below expectations, according to the report. CarMax said it expects about $200M in SG&A savings and ~$35 per unit in extended protection plans.

$KMXMed

CarMax shares drop as margin pressure overshadows strong quarterly results

CarMax shares fell over 6% despite a strong Q1. The company reported adjusted EPS of $1.31 vs $0.95 expected and revenue up 6.2% to $8.01B. However, investors focused on margin pressure: gross profit per retail used vehicle fell $230 to $2,177, with consecutive quarters of compression. CarMax Auto Finance income declined 1% to $140.2M as credit risk concerns rose.

$AZNHighAI 8/10

AstraZeneca Plunges After New Heart Disease Drug Fails Trial

AstraZeneca said its heart disease drug Wainua failed to beat placebo in a clinical trial for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), according to AstraZeneca and Ionis Pharmaceuticals. AstraZeneca shares fell up to 10.6% in London and 5.7% on the NYSE. Rival ATTR-CM drug makers Pfizer, BridgeBio, and Alnylam initially moved higher or lower.